1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

5,013.50
INR
-1.50
(-0.03%)
184.34EPS
30.87P/E
665.98BMarket Cap
Nov 06Next Earn
Alkem Laboratories Ltd.
NSE:ALKEM
(National Stock Exchange of India)

Recent

price

5,013.50

P/E

ratio

30.87

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
138.19
160.5
190.43
257.25
310.52
406.93
469.72
527.22
607.69
685.15
730.01
879.19
956.83
1,040.37
1,070.93
1,215.43
1,261.24
Revenue per Share
27.05
35.58
41.49
36.71
32.75
62.02
74.61
52.77
63.61
94.26
132.57
137.63
82.31
150.19
181.11
192.51
180.43
Basic EPS, GAAP
60.28
-7.59
27.83
15.58
15.67
39.19
-14.53
-34.94
20.95
18.57
89.49
64.58
121.24
141.24
103.48
112.56
- -
Free Cash Flow per Basic Share
1.75
1.75
4.32
2.66
4.74
15.43
7.22
18.2
18.28
36.76
28
35.29
44.29
45.2
42.2
51.33
- -
Dividend per Share
126.11
159.37
198.54
222.06
260.83
308.78
373.66
406.79
454.93
515.26
616.96
722.44
756.52
862.46
1,002.37
1,155.87
- -
Book Value per Share
125.92
159.24
197.02
203.43
227.11
273.78
339.99
372.47
419.4
464.93
570.21
682.69
715.32
822.79
957.4
1,078.56
- -
Tangible Book Value per Share
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
Basic Weighted Avg Shares
16,524
19,191
22,771
30,761
37,128
48,655
56,162
63,037
72,659
81,920
87,284
105,120
114,404
124,392
128,046
145,323
150,813
Sales/Revenue/Turnover
17.14
19.75
18.82
13.26
10.09
15.87
16.22
14.18
13.05
15.54
19.15
16.83
11.66
15.96
17.06
18.23
17.49
Operating Margin (%)
270
279
360
519
709
933
1,012
1,430
1,932
2,528
2,746
3,040
3,104
2,993
3,572
3,821
3,946
Depreciation Expense
3,234
4,255
4,961
4,390
3,916
7,416
8,920
6,309
7,605
11,271
15,850
16,456
9,842
17,958
21,655
23,018
21,575
Net Income, GAAP
8.95
6.36
2.7
2.12
13.14
18.98
6.22
31.05
18.96
8.77
12.18
8.89
22.84
10.46
12.31
18.03
23.18
Effective Tax Rate (%)
19.57
22.17
21.79
14.27
10.55
15.24
15.88
10.01
10.47
13.76
18.16
15.65
8.6
14.44
16.91
15.84
14.31
Profit Margin (%)
10,011
10,985
10,607
2,486
3,303
12,311
12,275
16,299
20,259
22,611
33,248
36,301
50,225
64,170
69,789
74,278
- -
Working Capital
669
1,272
923
2,400
393
1,235
1,816
1,307
2,313
739
976
759
703
2,293
5,783
8,692
- -
LT Debt
15,078
19,055
23,739
26,551
32,034
37,870
45,829
49,853
55,720
63,090
75,580
88,473
94,350
107,144
124,336
143,489
- -
Total Equity
14.65
14.28
13.11
10.5
7.55
14.1
17.46
11.01
12.27
16.08
17.52
15.37
8.42
14.54
14.73
13.46
- -
Return on Invested Capital (%)
20.29
19.07
18.01
14.22
11.07
17.54
18.9
11.73
12.6
15.96
18.45
15.8
9.25
16.25
16.9
15.54
- -
Return on Capital (%)
23.84
24.93
23.19
17.46
13.56
21.78
21.86
13.52
14.76
19.43
23.42
20.55
11.13
18.55
19.42
17.84
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
11,779
- -
LT Borrowings
- -
4,925
- -
LT Finance Leases
- -
3,768
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
660,780
633,575
665,977

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
122,105
- -
Cash, Cash Equivalents & STI
- -
40,652
- -
Accounts Receivable, Net
- -
29,791
- -
Inventories
- -
33,332
- -
Total Current Liabilities
- -
47,827
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
11,779
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.33%
13.74%
15.4%
Free Cash Flow
27.25%
11.69%
8.77%
Net Income, GAAP
17.34%
14.6%
6.3%
Sales/Revenue/Turnover
11.66%
10.88%
13.49%
Total Cash Common Dividend
24.51%
13.72%
21.62%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
30,318
34,147
33,743
31,438
128,046
2026
33,711
40,010
37,368
36,033
145,323
2027
37,402
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
45.6
57.6
52.34
25.57
181.11
2026
55.56
63.99
53.19
19.77
192.51
2027
43.49
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
42.2
2026
- -
- -
- -
- -
51.33
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Alkem Laboratories Limited Alkem Laboratories Limited (ALKEM.NS) manufactures and markets a broad portfolio of branded generics, generic drugs, active pharmaceutical ingredients, nutraceuticals, biosimilars, and specialty pharmaceuticals across acute and chronic therapy areas including anti-infectives, gastro-intestinal, pain management/analgesics, vitamins/minerals/nutrients, cardiology, dermatology, neurology/central nervous system, anti-diabetic, oncology, respiratory, rheumatology, and urology; prominent brands such as Clavam, Pan, Pan-D, and Taxim-O rank among India's top 50 pharmaceutical brands, with leadership sustained for over a decade in anti-infectives and strong positions in gastro-intestinal and vitamins/minerals/nutrients segments. Founded in 1973 and headquartered in Mumbai, India, at Alkem House, Senapati Bapat Marg, Lower Parel, the company operates 19 state-of-the-art manufacturing facilities in India and additional sites in the United States, several approved by US FDA, TGA, and UK MHRA, supporting a global footprint in over 40 countries with subsidiaries and operations emphasizing the US as its second-largest market after India, where international sales contribute approximately 32% of total revenue. Alkem Laboratories invests significantly in research and development across five global centers with over 500 scientists, focusing on generics, biosimilars, transdermal systems, oral films, and novel drug delivery systems, evidenced by cumulative filings of over 300 Abbreviated New Drug Applications with the US FDA and ongoing expansions in complex generics. In recent developments, the company completed the acquisition of 100% stake in Adroit Biomed Limited in April 2025 for Rs 140 crore, bolstering its dermatology and cosmetology portfolio, alongside investments in Bombay Ortho Industries to enhance medical technology capabilities in orthopedic implants, aligning with strategic diversification into high-growth segments and MedTech. These moves follow prior expansions, including US facility acquisitions and brand purchases like Clindac-A from Galderma in 2014, reinforcing Alkem's position among India's top pharmaceutical companies by market capitalization and domestic sales.